Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)

10/23/2020 | 05:14pm EST

Item 2.01. Completion of Acquisition or Disposition of Assets.

As previously disclosed, on September 13, 2020, Gilead Sciences, Inc., a Delaware corporation ("Parent" or "Gilead"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), among Parent, Immunomedics, Inc., a Delaware corporation ("Immunomedics"), and Maui Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"). In accordance with the terms of the Merger Agreement, on October 23, 2020, Gilead completed the acquisition of Immunomedics.

Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on September 24, 2020, Purchaser commenced a tender offer (the "Offer"), to purchase all of the issued and outstanding shares (the "Shares") of common stock, par value $0.01 per share, of Immunomedics, other than any Shares held immediately prior to the effective time of the Merger by Immunomedics (or held in Immunomedics' treasury) and any Shares held immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or indirect wholly owned subsidiary of Parent, at a price of $88.00 per Share (the "Offer Price"), net to the seller in cash, without interest and subject to any required withholding of taxes.

The Offer expired at one minute after 11:59 p.m., Eastern Time, on October 22, 2020. According to Computershare Trust Company, N.A., the depositary for the Offer, 188,227,162 Shares were validly tendered and not withdrawn in the Offer, representing approximately 81.38% of the outstanding Shares (not including 12,451,797 Shares delivered through Notices of Guaranteed Delivery, representing approximately 5.38% of the Shares outstanding). The number of Shares tendered satisfied the condition to the Offer that there be validly tendered and not validly withdrawn prior to the expiration of the Offer a number of Shares that, considered together with all other Shares (if any) beneficially owned by Parent and its affiliates, represent one more Share than 50% of the total number of Shares outstanding at the expiration of the Offer (excluding Shares tendered by notice of guaranteed delivery that have not yet been "received" (as such term is defined in Section 251(h)(6)(f) of the General Corporation Law of the State of Delaware (the "DGCL"))). All conditions to the Offer having been satisfied or waived, Gilead and Purchaser accepted for payment all Shares validly tendered and not validly withdrawn.

Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and on October 23, 2020, Purchaser merged with and into Immunomedics pursuant to Section 251(h) of the DGCL, with Immunomedics being the surviving corporation (the "Merger"). At the effective time of the Merger, each Share (other than (i) Shares held by Immunomedics (or held in Immunomedics' treasury), (ii) Shares held by Parent, Purchaser, or any other direct or indirect wholly owned subsidiary of Parent and (iii) Shares held by stockholders who have properly exercised and perfected their demands for appraisal of such Shares in accordance with the DGCL and have neither withdrawn nor lost such rights prior to the effective time of the Merger) converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any required withholding of taxes.

The aggregate consideration paid by Gilead to acquire the Shares in the Offer and Merger was approximately $21 billion. Gilead obtained the funds necessary to fund the acquisition through (i) proceeds from the borrowings under the Term Loan Facility Credit Agreement dated October 23, 2020 among Gilead, as borrower, each lender from time to time party thereto and Barclays Bank PLC, as administrative agent, consisting of a $1 billion senior unsecured term loan facility, (ii) proceeds from the offering of senior unsecured notes, consisting of $500 million aggregate principal amount of floating rate notes due 2021, $500 million aggregate principal amount of floating rate notes due 2023, $2 billion aggregate principal amount of 0.75% senior notes due 2023, $1 billion aggregate principal amount of 1.65% senior notes due 2030 and $1 billion aggregate principal amount of 2.60% senior notes due 2040, on the terms and conditions previously disclosed in the final prospectus supplement filed by Gilead with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on September 25, 2020 and (iii) cash on hand.

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as

Exhibit 2.1 to the Current Report on Form 8-K filed by Gilead with the Securities and Exchange Commission on September 14, 2020 and which is incorporated by reference herein .


 Item 8.01. Other Events.



On October 23, 2020, Gilead issued a press release announcing the completion of the acquisition of Immunomedics, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired

The financial statements of Immunomedics required by this item will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed.

(b) Pro Forma Financial Information

The pro forma financial information required by this item will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed.




(d) Exhibits




Exhibit
Number     Description
  2.1*       Agreement and Plan of Merger, dated September 13, 2020, among
           Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc.
           (incorporated by reference to Exhibit 2.1 to the Current Report on
           Form 8-K filed by Gilead with the Securities and Exchange Commission
           on September 14, 2020).

  99.1       Press Release, dated October 23, 2020.

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document).





* Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Gilead

Sciences, Inc. agrees to furnish supplementally a copy of any omitted schedule

to the SEC upon request.

© Edgar Online, source Glimpses

All news about GILEAD SCIENCES, INC.
11/25EU seeks to bypass patents to boost drugs access in crises
RE
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
AQ
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
BU
11/23Canada could approve COVID-19 vaccines early next year -regulator
RE
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
RE
11/22FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
RE
11/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
11/20Health Care Down, But Not By Much, Amid Vaccine Optimism -- Health Care Round..
DJ
11/20Post Holdings, Gilead Sciences fall; Pfizer, Hibbett rise
AQ
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 404x
Yield 2020 4,54%
Capitalization 75 249 M 75 249 M -
EV / Sales 2020 4,05x
EV / Sales 2021 3,86x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 60,03 $
Spread / Highest target 74,9%
Spread / Average Target 22,5%
Spread / Lowest Target -3,38%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-7.62%75 249
WUXI APPTEC CO., LTD.56.53%37 916
BEIGENE, LTD.72.47%26 060
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928
SPRINGWORKS THERAPEUTICS, INC.76.67%3 259
AXSOME THERAPEUTICS, INC.-27.26%2 808